Abstract
Gene therapy for sickle cell disease (SCD) can drastically transform an individual's life and decrease the disease burden, but there are several ethical dilemmas associated with it. This editorial examines the various challenges, including the quality of informed consent, patient selection criteria, and equitable access. While gene therapy offers significant promise, addressing the ethical concerns surrounding it is crucial to ensure responsible implementation and equitable care for individuals with SCD and their communities.